Development of pain therapies targeting nerve growth factor signal transduction and the strategies used to resolve safety issues

Journal of Toxicological Sciences

Volumn 43, Issue 1, 2018, Pages 1-10

  Bélanger, Patrice ^a   West, Christine R ^a   Brown, Mark T ^a  

^a PFIZER INC   (United States)

Author keywords

Fasinumab; Fulranumab; Nerve growth factor antibody; Tanezumab

Indexed keywords

FASINUMAB; FULRANUMAB; NERVE GROWTH FACTOR; NERVE GROWTH FACTOR ANTIBODY; TANEZUMAB; MONOCLONAL ANTIBODY;

ARTHROPATHY; BONE REMODELING; CELL DEATH; CHRONIC PAIN; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG TOLERABILITY; FRACTURE HEALING; GENETIC TRANSCRIPTION; HUMAN; OSTEOARTHRITIS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; ANIMAL; GENETICS; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; PHYSIOLOGY;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; CHRONIC PAIN; HUMANS; MOLECULAR TARGETED THERAPY; NERVE GROWTH FACTOR; SIGNAL TRANSDUCTION;

EID: 85041901791     PISSN: 03881350     EISSN: 18803989     Source Type: Journal    
DOI: 10.2131/jts.43.1     Document Type: Review

References (68)

1. Abdiche, Y.N., Malashock, D.S. and Pons, J. (2008): Probing the binding mechanism and affinity of tanezumab, a recombinant humanized anti-NGF monoclonal antibody, using a repertoire of biosensors. Protein Sci., 17, 1326-1335.
2. Balanescu, A.R., Feist, E., Wolfram, G., Davignon, I., Smith, M.D., Brown, M.T. and West, C.R. (2014): Efficacy and safety of tanezumab added on to diclofenac sustained release in patients with knee or hip osteoarthritis: a double-blind, placebo-controlled, parallel-group, multicentre phase III randomised clinical trial. Ann. Rheum. Dis., 73, 1665-1672.
3. Belanger, P., Butler, P., Butt, M., Bhatt, S., Foote, S., Shelton, D., Evans, M., Arends, R., Hurst, S., Okerberg, C., Cummings, T., Potter, D., Steidl-Nichols, J. and Zorbas, M. (2017): Evaluation of the Effects of Tanezumab, a Monoclonal Antibody Against Nerve Growth Factor, on the Sympathetic Nervous System in Adult Cynomolgus Monkeys (Macaca fascicularis): A Stereologic, Histomorphologic, and Cardiofunctional Assessment. Toxicol Sci., 158, 319-333.
4. Bennett, D.L., Koltzenburg, M., Priestley, J.V., Shelton, D.L. and McMahon, S.B. (1998): Endogenous nerve growth factor regulates the sensitivity of nociceptors in the adult rat. Eur. J. Neurosci., 10, 1282-1291.
5. Bjerre, B., Wiklund, L. and Edwards, D.C. (1975): A study of the de- and regenerative changes in the sympathetic nervous system of the adult mouse after treatment with the antiserum to nerve growth factor. Brain Res., 92, 257-278.
6. Bjordal, J.M., Ljunggren, A.E., Klovning, A. and Slordal, L. (2004): Non-steroidal anti-inflammatory drugs, including cyclo-oxyge-nase-2 inhibitors, in osteoarthritic knee pain: meta-analysis of randomised placebo controlled trials. BMJ, 329, 1317.
7. Bramson, C., Herrmann, D.N., Carey, W., Keller, D., Brown, M.T., West, C.R., Verburg, K.M. and Dyck, P.J. (2015): Exploring the role of tanezumab as a novel treatment for the relief of neuro-pathic pain. Pain Med., 16, 1163-1176.
8. Brown, M.T., Herrmann, D.N., Goldstein, M., Burr, A.M., Smith, M.D., West, C.R., Verburg, K.M. and Dyck, P.J. (2014): Nerve safety of tanezumab, a nerve growth factor inhibitor for pain treatment. J. Neurol. Sci., 345, 139-147.
9. Brown, M.T., Murphy, F.T., Radin, D.M., Davignon, I., Smith, M.D. and West, C.R. (2012): Tanezumab reduces osteoarthritic knee pain: results of a randomized, double-blind, placebo-controlled phase III trial. J. Pain, 13, 790-798.
10. Brown, M.T., Murphy, F.T., Radin, D.M., Davignon, I., Smith, M.D. and West, C.R. (2013): Tanezumab reduces osteoarthritic hip pain: results of a randomized, double-blind, placebo-controlled phase III trial. Arthritis Rheum., 65, 1795-1803.
11. Bueker, E.D. (1948): Implantation of tumors in the hind limb field of the embryonic chick and the developmental response of the lumbosacral nervous system. Anat. Rec., 102, 369-389.
12. Butt, M., Evans, M., Bowman, C.J., Cummings, T., Oneda, S., Shelton, D. and Zorbas, M. (2014): Morphologic, stereologic, and morphometric evaluation of the nervous system in young cynomolgus monkeys (Macaca fascicularis) following maternal administration of tanezumab, a monoclonal antibody to nerve growth factor. Toxicol. Sci., 142, 463-476.
13. Center for Drug Evaluation and Research (2012a): Background materials. Addendum. US Food and Drug Administration, Silver Spring, MD, USA. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisDrugsAdvisoryCommittee/UCM295203.pdf (accessed March 3, 2017).
14. Center for Drug Evaluation and Research (2012b): Background materials. Meeting of the Arthritis Advisory Committee (AAC). US Food and Drug Administration, Silver Spring, MD, USA. Available at: http://www.fda.gov/downloads/AdvisoryCommit-tees/CommitteesMeetingMaterials/Drugs/ArthritisDrugsAdviso-ryCommittee/UCM295202.pdf (accessed March 3, 2017).
15. Delcroix, J.D., Valletta, J.S., Wu, C., Hunt, S.J., Kowal, A.S. and Mobley, W.C. (2003): NGF signaling in sensory neurons: evidence that early endosomes carry NGF retrograde signals. Neuron, 39, 69-84.
16. Dyck, P.J., Peroutka, S., Rask, C., Burton, E., Baker, M.K., Lehman, K.A., Gillen, D.A., Hokanson, J.L. and O’Brien, P.C. (1997): Intradermal recombinant human nerve growth factor induces pressure allodynia and lowered heat-pain threshold in humans. Neurology, 48, 501-505.
17. Ekman, E.F., Gimbel, J.S., Bello, A.E., Smith, M.D., Keller, D.S., Annis, K.M., Brown, M.T., West, C.R. and Verburg, K.M. (2014): Efficacy and safety of intravenous tanezumab for the symptomatic treatment of osteoarthritis: 2 randomized controlled trials versus naproxen. J. Rheumatol., 41, 2249-2259.
18. Ghi lardi, J. R., Freeman, K. T., Jimenez-Andrade, J. M., Coughlin, K.A., Kaczmarska, M.J., Castaneda-Corral, G., Bloom, A.P., Kuskowski, M.A. and Mantyh, P.W. (2012): Neu-roplasticity of sensory and sympathetic nerve fibers in a mouse model of a painful arthritic joint. Arthritis Rheum., 64, 2223-2232.
19. Gimbel, J.S., Kivitz, A.J., Bramson, C., Nemeth, M.A., Keller, D.S., Brown, M.T., West, C.R. and Verburg, K.M. (2014): Long-term safety and effectiveness of tanezumab as treatment for chronic low back pain. Pain, 155, 1793-1801.
20. Goedert, M., Otten, U. and Thoenen, H. (1978): Biochemical effects of nerve growth factor and its antibody on the vas defferens and the adrenal medulla. Neurosci. Lett., 8, 71-76.
21. Gorin, P.D. and Johnson, E.M. (1979): Experimental autoimmune model of nerve growth factor deprivation: effects on developing peripheral sympathetic and sensory neurons. Proc. Natl. Acad. Sci. USA, 76, 5382-5386.
22. Gorin, P.D. and Johnson, E.M. Jr. (1980): Effects of long-term nerve growth factor deprivation on the nervous system of the adult rat: an experimental autoimmune approach. Brain Res., 198, 27-42.
23. Halvorson, K.G., Kubota, K., Sevcik, M.A., Lindsay, T.H., Sotillo, J.E., Ghilardi, J.R., Rosol, T.J., Boustany, L., Shelton, D.L. and Mantyh, P.W. (2005): A blocking antibody to nerve growth factor attenuates skeletal pain induced by prostate tumor cells growing in bone. Cancer Res., 65, 9426-9435.
24. Hefti, F.F., Rosenthal, A., Walicke, P.A., Wyatt, S., Vergara, G., Shelton, D.L. and Davies, A.M. (2006): Novel class of pain drugs based on antagonism of NGF. Trends Pharmacol. Sci., 27, 85-91.
25. Hochberg, M.C. (2015): Serious joint-related adverse events in randomized controlled trials of anti-nerve growth factor monoclonal antibodies. Osteoarthritis Cartilage, 23 Suppl 1, S18-21.
26. Hochberg, M.C., Tive, L.A., Abramson, S.B., Vignon, E., Verburg, K.M., West, C.R., Smith, M.D. and Hungerford, D.S. (2016): When is osteonecrosis not osteonecrosis?: Adjudication of reported serious adverse joint events in the tanezumab clinical development program. Arthritis Rheumatol., 68, 382-391.
27. Institute of Medicine (2011): Relieving pain in America: a blueprint for transforming prevention, care, education, and research. National Academies Press, Washington DC.
28. Janssen Research and Development LLC (2012): Arthritis Advisory Committee Briefing Document. JNJ-42160443 (fulranumab). Janssen, Raritan, NJ, USA. Available at: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisoryCommittee/UCM295204.pdf (accessed March 3, 2017).
29. Janssen Research and Development LLC (2016): Janssen announces discontinuation of fulranumab phase 3 development program in osteoarthritis pain. Janssen, Titusville, NJ, USA. Available at: http://www.prnewswire.com/news-releases/janssen-announc-es-discontinuation-of-fulranumab-phase-3-development-pro-gram-in-osteoarthritis-pain-300244240.html (accessed March 3, 2017).
30. Jimenez-Andrade, J.M., Ghilardi, J.R., Castañeda-Corral, G., Kuskowski, M.A. and Mantyh, P.W. (2011): Preventive or late administration of anti-NGF therapy attenuates tumor-induced nerve sprouting, neuroma formation, and cancer pain. Pain, 152, 2564-2574.
31. Jimenez-Andrade, J.M., Martin, C.D., Koewler, N.J., Freeman, K.T., Sullivan, L.J., Halvorson, K.G., Barthold, C.M., Peters, C.M., Buus, R.J., Ghilardi, J.R., Lewis, J.L., Kuskowski, M.A. and Mantyh, P.W. (2007): Nerve growth factor sequestering therapy attenuates non-malignant skeletal pain following fracture. Pain, 133, 183-196.
32. Johnson, E.M. Jr., Gorin, P.D., Osborne, P.A., Rydel, R.E. and Pearson, J. (1982): Effects of autoimmune NGF deprivation in the adult rabbit and offspring. Brain Res., 240, 131-140.
33. Katz, N., Borenstein, D.G., Birbara, C., Bramson, C., Nemeth, M.A., Smith, M.D. and Brown, M.T. (2011): Efficacy and safety of tanezumab in the treatment of chronic low back pain. Pain, 152, 2248-2258.
34. Kendall, G., Brar-Rai, A., Ensor, E., Winter, J., Wood, J.N. and Latchman, D.S. (1995): Nerve growth factor induces the Oct-2 transcription factor in sensory neurons with the kinetics of an immediate-early gene. J. Neurosci. Res., 40, 169-176.
35. Kissin, I. (2010): The development of new analgesics over the past 50 years: a lack of real breakthrough drugs. Anesth. Analg., 110, 780-789.
36. Kivitz, A.J., Gimbel, J.S., Bramson, C., Nemeth, M.A., Keller, D.S., Brown, M.T., West, C.R. and Verburg, K.M. (2013): Efficacy and safety of tanezumab versus naproxen in the treatment of chronic low back pain. Pain, 154, 1009-1021.
37. Koewler, N.J., Freeman, K.T., Buus, R.J., Herrera, M.B., Jimenez-Andrade, J.M., Ghilardi, J.R., Peters, C.M., Sullivan, L.J., Kuskowski, M.A., Lewis, J.L. and Mantyh, P.W. (2007): Effects of a monoclonal antibody raised against nerve growth factor on skeletal pain and bone healing after fracture of the C57BL/6J mouse femur. J. Bone Miner. Res., 22, 1732-1742.
38. Lane, N.E., Schnitzer, T.J., Birbara, C.A., Mokhtarani, M., Shelton, D.L., Smith, M.D. and Brown, M.T. (2010): Tanezumab for the treatment of pain from osteoarthritis of the knee. N. Engl. J. Med., 363, 1521-1531.
39. Levi-Montalcini, R. and Booker, B. (1960): Destruction of the sympathetic ganglia in mammals by an antiserum to a nerve-growth protein. Proc. Natl. Acad. Sci. USA, 46, 384-391.
40. Lewin, G.R., Rueff, A. and Mendell, L.M. (1994): Peripheral and central mechanisms of NGF-induced hyperalgesia. Eur. J. Neurosci., 6, 1903-1912.
41. Mantyh, P.W., Koltzenburg, M., Mendell, L.M., Tive, L. and Shelton, D.L. (2011): Antagonism of nerve growth factor-TrkA signaling and the relief of pain. Anesthesiology, 115, 189-204.
42. Mayorga, A.J., Wang, S., Kelly, K.M. and Thipphawong, J. (2016): Efficacy and safety of fulranumab as monotherapy in patients with moderate to severe, chronic knee pain of primary osteoarthritis: a randomised, placebo- and active-controlled trial. Int. J. Clin. Pract., 70, 493-505.
43. McMahon, S.B. (1996): NGF as a mediator of inflammatory pain. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 351, 431-440.
44. Miller, F.D. and Kaplan, D.R. (2001): On Trk for retrograde signaling. Neuron, 32, 767-770.
45. Nagashima, H., Suzuki, M., Araki, S., Yamabe, T. and Muto, C. (2011): Preliminary assessment of the safety and efficacy of tanezumab in Japanese patients with moderate to severe osteoarthritis of the knee: a randomized, double-blind, dose-escalation, placebo-controlled study. Osteoarthritis Cartilage, 19, 1405-1412.
46. Pfizer Inc. (2012): Arthritis Advisory Committee Briefing Document. Available at: http://www.fda.gov/downloads/Advisory-Committees/CommitteesMeetingMaterials/Drugs/ArthritisDrug-sAdvisoryCommittee/UCM295205.pdf; accessed November 23, 2016.
47. Pfizer Inc. (2015): Pfizer And Lilly preparing to resume phase 3 chronic pain program for tanezumab. Pfizer, New York, NY, USA. Available at: http://www.pfizer.com/news/press-release/press-release-detail/pfizer_and_lilly_preparing_to_resume_ phase_3_chronic_pain_program_for_tanezumab (accessed March 3, 2017).
48. Regeneron Inc. (2016a): Regeneron and Teva provide update on fasinumab clinical development programs. Regeneron, Tarrytown, NY, USA. Available at: http://newsroom.regeneron.com/releasedetail.cfm?ReleaseID=993787 (accessed March 3, 2017).
49. Regeneron Inc. (2016b): Regeneron announces positive topline results from phase 2/3 fasinumab study in patients with osteoarthritis pain. Regeneron, Tarrytown, NY, USA. Available at: http://files.shareholder.com/downloads/REGN/2409042285x0x8 89001/920E5C9C-AA16-4E97-98B7-8EFC55D0BD35/REGN_ News_2016_5_2_General_Releases.pdf (accessed March 1, 2017).
50. Regeneron Pharmaceuticals Inc. and Arthritis Advisory Committee Meeting (2012): REGN475: Arthritis Advisory Committee briefing book. Regeneron Pharmaceuticals, Eastview, NY, USA. Available at: http://www.fda.gov/downloads/AdvisoryCommit-tees/CommitteesMeetingMaterials/Drugs/ArthritisAdvisory-Committee/UCM295206.pdf (accessed March 1, 2017).
51. Ruberti, F., Capsoni, S., Comparini, A., Di Daniel, E., Franzot, J., Gonfloni, S., Rossi, G., Berardi, N. and Cattaneo, A. (2000): Phenotypic knockout of nerve growth factor in adult transgen-ic mice reveals severe deficits in basal forebrain cholinergic neurons, cell death in the spleen, and skeletal muscle dystrophy. J. Neurosci., 20, 2589-2601.
52. Ruit, K.G., Osborne, P.A., Schmidt, R.E., Johnson, E.M., Jr. and Snider, W.D. (1990): Nerve growth factor regulates sympathetic ganglion cell morphology and survival in the adult mouse. J. Neurosci., 10, 2412-2419.
53. Sabsovich, I., Wei, T., Guo, T.Z., Zhao, R., Shi, X., Li, X., Yeomans, D.C., Klyukinov, M., Kingery, W.S. and Clark, J.D. (2008): Effect of anti-NGF antibodies in a rat tibia fracture model of complex regional pain syndrome type I. Pain, 138, 47-60.
54. Sanga, P., Katz, N., Polverejan, E., Wang, S., Kelly, K.M., Haeussler, J. and Thipphawong, J. (2013): Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain. Pain, 154, 1910-1919.
55. Sanga, P., Polverejan, E., Wang, S., Kelly, K.M. and Thipphawong, J. (2016): Efficacy, safety, and tolerability of fulranumab as an adjunctive therapy in patients with inadequately controlled, moderate-to-severe chronic low back pain: a randomized, double-blind, placebo-controlled, dose-ranging, dose-loading phase II study. Clin. Ther., 38, 1435-1450.
56. Schnitzer, T.J., Ekman, E.F., Spierings, E.L., Greenberg, H.S., Smith, M.D., Brown, M.T., West, C.R. and Verburg, K.M. (2015): Efficacy and safety of tanezumab monotherapy or combined with non-steroidal anti-inflammatory drugs in the treat- ment of knee or hip osteoarthritis pain. Ann. Rheum. Dis., 74, 1202-1211.
57. Schnitzer, T.J., Lane, N.E., Birbara, C., Smith, M.D., Simpson, S.L. and Brown, M.T. (2011): Long-term open-label study of tanezumab for moderate to severe osteoarthritic knee pain. Osteoarthritis Cartilage, 19, 639-646.
58. Sevcik, M.A., Ghilardi, J.R., Peters, C.M., Lindsay, T.H., Halvorson, K.G., Jonas, B.M., Kubota, K., Kuskowski, M.A., Boustany, L., Shelton, D.L. and Mantyh, P.W. (2005): Anti-NGF therapy profoundly reduces bone cancer pain and the accompanying increase in markers of peripheral and central sensitization. Pain, 115, 128-141.
59. Shelton, D.L., Vergara, G., Pons, J., Ho, W.H. and Stratton, J. (2008): Effect of PF04383119 on post-incisional pain following IV or IP administration. Anesthesiology, 109, A1539.
60. Shelton, D.L., Zeller, J., Ho, W.H., Pons, J. and Rosenthal, A. (2005): Nerve growth factor mediates hyperalgesia and cachexia in auto-immune arthritis. Pain, 116, 8-16.
61. Sopata, M., Katz, N., Carey, W., Smith, M.D., Keller, D., Verburg, K.M., West, C.R., Wolfram, G. and Brown, M.T. (2015): Efficacy and safety of tanezumab in the treatment of pain from bone metastases. Pain, 156, 1703-1713.
62. Spierings, E.L., Fidelholtz, J., Wolfram, G., Smith, M.D., Brown, M.T. and West, C.R. (2013): A phase III placebo- and oxyco- done-controlled study of tanezumab in adults with osteoarthritis pain of the hip or knee. Pain, 154, 1603-1612.
63. Svensson, P., Cairns, B.E., Wang, K. and Arendt-Nielsen, L. (2003): Injection of nerve growth factor into human masseter muscle evokes long-lasting mechanical allodynia and hyperalgesia. Pain, 104, 241-247.
64. Tiseo, P.J., Kivitz, A.J., Ervin, J.E., Ren, H. and Mellis, S.J. (2014): Fasinumab (REGN475), an antibody against nerve growth factor for the treatment of pain: results from a double-blind, placebo-controlled exploratory study in osteoarthritis of the knee. Pain, 155, 1245-1252.
65. Woolf, C.J. (1996): Phenotypic modification of primary sensory neurons: the role of nerve growth factor in the production of persistent pain. Philos. Trans. R. Soc. Lond. B. Biol. Sci., 351, 441-448.
66. Woolf, C.J. and Max, M.B. (2001): Mechanism-based pain diagnosis: issues for analgesic drug development. Anesthesiology, 95, 241-249.
67. Wu, C., Boustany, L., Liang, H. and Brennan, T.J. (2007): Nerve growth factor expression after plantar incision in the rat. Anesthesiology, 107, 128-135.
68. Zahn, P.K., Subieta, A., Park, S.S. and Brennan, T.J. (2004): Effect of blockade of nerve growth factor and tumor necrosis factor on pain behaviors after plantar incision. J. Pain, 5, 157-163.